The formation of idic(Ph) chromosomes may play a crucial role in the amplification and heterogeneity of the BCR-ABL gene, leading to resistance to IM therapy in CML patients (8). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.